ANGPT1
Angiopoietin-1
As of the edition of 20 October 2026, ANGPT1 (angiopoietin-1, UniProt Q15389) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q15389
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 5
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Hormones; Skin and connective tissue; Digestive system; Nervous system; Blood and lymph
- Registered trials of its drugs
- 30
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Trebananib | Stopped | Phase 3 | none listed |
| AMG-780 | Stopped | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 2 |